MX2023006488A - Methods and compositions for neoadjuvant and adjuvant urothelial carcinoma therapy. - Google Patents

Methods and compositions for neoadjuvant and adjuvant urothelial carcinoma therapy.

Info

Publication number
MX2023006488A
MX2023006488A MX2023006488A MX2023006488A MX2023006488A MX 2023006488 A MX2023006488 A MX 2023006488A MX 2023006488 A MX2023006488 A MX 2023006488A MX 2023006488 A MX2023006488 A MX 2023006488A MX 2023006488 A MX2023006488 A MX 2023006488A
Authority
MX
Mexico
Prior art keywords
compositions
urothelial carcinoma
neoadjuvant
patient
adjuvant
Prior art date
Application number
MX2023006488A
Other languages
Spanish (es)
Inventor
Sanjeev Mariathasan
Chi Yung Yuen
Zoe June Fergusson Assaf
Romain Francois Banchereau
Carlos Ernesto Bais
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2023006488A publication Critical patent/MX2023006488A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention provides methods and compositions for treating urothelial carcinoma in a patient, for example, by administering a treatment regimen that includes a PD-1 axis binding antagonist (e.g., atezolizumab) to the patient as a neoadjuvant or an adjuvant therapy based on the presence or level of ctDNA in a biological sample obtained from the patient. Also provided are compositions (e.g., a PD-1 axis binding antagonist (e.g., atezolizumab), pharmaceutical compositions thereof, kits thereof, and articles of manufacture thereof) for use in treating urothelial carcinoma in a patient.
MX2023006488A 2020-12-02 2021-11-30 Methods and compositions for neoadjuvant and adjuvant urothelial carcinoma therapy. MX2023006488A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063120643P 2020-12-02 2020-12-02
US202163210950P 2021-06-15 2021-06-15
PCT/US2021/061185 WO2022119830A1 (en) 2020-12-02 2021-11-30 Methods and compositions for neoadjuvant and adjuvant urothelial carcinoma therapy

Publications (1)

Publication Number Publication Date
MX2023006488A true MX2023006488A (en) 2023-06-20

Family

ID=79021931

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006488A MX2023006488A (en) 2020-12-02 2021-11-30 Methods and compositions for neoadjuvant and adjuvant urothelial carcinoma therapy.

Country Status (9)

Country Link
US (1) US20240141437A1 (en)
EP (1) EP4255481A1 (en)
JP (1) JP2023551906A (en)
KR (1) KR20230117162A9 (en)
AU (1) AU2021392630A1 (en)
CA (1) CA3202523A1 (en)
IL (1) IL303256A (en)
MX (1) MX2023006488A (en)
WO (1) WO2022119830A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024049949A1 (en) * 2022-09-01 2024-03-07 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
WO2024077095A1 (en) * 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer
WO2024097217A1 (en) * 2022-11-01 2024-05-10 Petdx, Inc. Detection of non-cancer somatic mutations

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
SI2439273T1 (en) 2005-05-09 2019-05-31 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
CN101248089A (en) 2005-07-01 2008-08-20 米德列斯公司 Human monoclonal antibodies to programmed death ligand 1(PD-L1)
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme Pd-1 binding proteins
JP2012510429A (en) 2008-08-25 2012-05-10 アンプリミューン、インコーポレーテッド PD-1 antagonist and method of use thereof
UA109108C2 (en) 2008-12-09 2015-07-27 Дженентек, Інк. Anti-pd-ll antibody and its use to enhance t-cell function
US10113196B2 (en) 2010-05-18 2018-10-30 Natera, Inc. Prenatal paternity testing using maternal blood, free floating fetal DNA and SNP genotyping
ES2646863T3 (en) 2009-11-24 2017-12-18 Medimmune Limited B7-H1 specific binding agents
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
DK2699264T3 (en) 2011-04-20 2018-06-25 Medimmune Llc ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
EP2717895A1 (en) 2011-06-08 2014-04-16 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
WO2013132317A1 (en) 2012-03-07 2013-09-12 Aurigene Discovery Technologies Limited Peptidomimetic compounds as immunomodulators
AU2013239366A1 (en) 2012-03-29 2014-10-16 Aurigene Discovery Technologies Limited Immunomodulating cyclic compounds from the BC loop of human PD1
KR102410078B1 (en) 2012-05-31 2022-06-22 소렌토 쎄라퓨틱스, 인코포레이티드 Antigen binding proteins that bind pd-l1
SG11201508528TA (en) 2013-05-02 2015-11-27 Anaptysbio Inc Antibodies directed against programmed death-1 (pd-1)
US9676853B2 (en) 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
CN104250302B (en) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 The anti-antibody of PD 1 and its application
MX365218B (en) 2013-09-06 2019-05-27 Aurigene Discovery Tech Ltd 1,2,4-oxadiazole derivatives as immunomodulators.
EA031325B1 (en) 2013-09-06 2018-12-28 Ауриген Дискавери Текнолоджиз Лимитед Cyclic peptidomimetic compounds as immunomodulators
CU24345B1 (en) 2013-09-06 2018-05-08 Aurigene Discovery Tech Ltd DERIVATIVES OF 1,3,4-OXADIAZOL AND 1,3,4-TIADIAZOL AS IMMUNOMODULATORS
WO2015036927A1 (en) 2013-09-10 2015-03-19 Aurigene Discovery Technologies Limited Immunomodulating peptidomimetic derivatives
PL3702373T3 (en) 2013-09-13 2022-12-05 Beigene Switzerland Gmbh Anti-pd1 antibodies and their use as therapeutics and diagnostics
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
SG10201804945WA (en) 2013-12-12 2018-07-30 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
TWI680138B (en) 2014-01-23 2019-12-21 美商再生元醫藥公司 Human antibodies to pd-l1
TWI681969B (en) 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
US10899840B2 (en) 2014-02-04 2021-01-26 Pfizer Inc. Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
CA3210360A1 (en) 2014-02-04 2015-08-13 Pfizer Inc. Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
KR102130600B1 (en) 2014-07-03 2020-07-08 베이진 엘티디 Anti-PD-L1 Antibodies and Their Use as Therapeutics and Diagnostics
CA2955676A1 (en) 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
TWI716362B (en) 2014-10-14 2021-01-21 瑞士商諾華公司 Antibody molecules to pd-l1 and uses thereof
SG11201703925VA (en) 2014-12-02 2017-06-29 Celgene Corp Combination therapies
WO2016106160A1 (en) 2014-12-22 2016-06-30 Enumeral Biomedical Holdings, Inc. Methods for screening therapeutic compounds
CN111213059B (en) 2017-11-06 2024-01-09 豪夫迈·罗氏有限公司 Diagnostic and therapeutic methods for cancer

Also Published As

Publication number Publication date
AU2021392630A1 (en) 2023-06-22
KR20230117162A9 (en) 2024-03-21
JP2023551906A (en) 2023-12-13
IL303256A (en) 2023-07-01
EP4255481A1 (en) 2023-10-11
WO2022119830A8 (en) 2022-07-21
US20240141437A1 (en) 2024-05-02
KR20230117162A (en) 2023-08-07
CA3202523A1 (en) 2022-06-09
WO2022119830A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
MX2023006488A (en) Methods and compositions for neoadjuvant and adjuvant urothelial carcinoma therapy.
MX2021005011A (en) Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7).
CY1124791T1 (en) CD73-SPECIFIC BINDING MOLECULES AND USES THEREOF
MX2020008882A (en) Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies.
MX2022006075A (en) Therapeutic and diagnostic methods for cancer.
MX2019009967A (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof.
BR112020016331A8 (en) METHODS TO TREAT CANCER WITH ANTI-PD-1 ANTIBODIES
BR112022002442A2 (en) IMMUNO-ONCOLOGY THERAPIES WITH IL-2 CONJUGATES
MX2016016744A (en) Ezh2 inhibitors for treating lymphoma.
BR112020015915A8 (en) USES OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-CTLA4 ANTIBODY OR ANTIGEN-BINDING FRAGMENTS THEREOF, AS WELL AS A KIT FOR TREATMENT OF A PATIENT WITH CANCER
ZA201907225B (en) Treatment of her2 positive cancers
EA201891473A1 (en) COMBINED THERAPY
MX2023004156A (en) Combination therapy for treating cancer.
MX2023004399A (en) Combination treatment.
MX2023004032A (en) Immuno oncology therapies with il-2 conjugates.
MX2023004869A (en) Antibodies against sars-cov-2 and uses thereof.
BR112015031950A2 (en) Methods for Ovarian Cancer Treatment
EA201792286A1 (en) METHODS OF TREATING CANCER
EA201991870A1 (en) TREATMENT OF BLADDER CANCER USING AN ANTIBODY TO PD-L1
CR20220127A (en) Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
BR112021016923A2 (en) Methods for treating a patient with hematologic cancer, methods for treating a patient with relapsed or refractory mm, methods for treating a patient having a relapsed or refractory lnh, and kits
MX2020011287A (en) Selecting patients for therapy with adenosine signaling inhibitors.
MX2022007516A (en) Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents.
BR112022001037A2 (en) Methods for treating or preventing cancers involving the administration of anti-ccr5 receptor agents
MX2022011027A (en) Compositions and methods for treatment of cancer.